Brief: Matinas Reports Positive Data In Ongoing EnACT Trial of MAT2203 For Treatment Of Cryptococcal Meningitis

Matinas BioPharma Holdings

13/09/2021 12:35

Sept 13 (Reuters) - Matinas BioPharma Holdings Inc  MTNB.A :
    * MATINAS BIOPHARMA ANNOUNCES POSITIVE DATA IN ONGOING ENACT
TRIAL
OF MAT2203 (ORAL AMPHOTERICIN B) FOR TREATMENT OF CRYPTOCOCCAL
MENINGITIS, EXCEEDING PRESPECIFIED PRIMARY ENDPOINT THRESHOLD
    * MATINAS BIOPHARMA HOLDINGS INC - STEP-DOWN THERAPY WITH
MAT2203
ACHIEVED EFFECTIVE CLEARANCE OF FUNGAL ORGANISMS
    * MATINAS BIOPHARMA HOLDINGS INC - MEAN EARLY FUNGICIDAL
ACTIVITY
(EFA) WAS 0.38, EXCEEDING PRESPECIFIED PRIMARY ENDPOINT
THRESHOLD TARGET OF >0.20
    * MATINAS BIOPHARMA HOLDINGS INC - OVERALL SURVIVAL WAS >95%
IN 40
PATIENTS RECEIVING MAT2203 IN COHORT 2
    * MATINAS BIOPHARMA HOLDINGS INC - ALL 39 PATIENTS
COMPLETING
INDUCTION WITH MAT2203 ACHIEVED STERILITY
    * MATINAS BIOPHARMA HOLDINGS - PREPARING TO ENGAGE WITH FDA
TO
REVIEW ENACT DATA AS SUPPORTIVE OF POTENTIAL EARLY APPROVAL OF
MAT2203 AS STEP-DOWN THERAPY

Source text for Eikon:  ID:nGNX13K4Lg 
Further company coverage:  MTNB.A 

 ((Reuters.Briefs@thomsonreuters.com;))